The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS ... It doesn't always become the invasive type of cancer that can spread outside the breast.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS ...

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

shedding light on ductal carcinoma in situ (DCIS), invasive ductal carcinoma, invasive lobular carcinoma, phyllodes tumor, Paget's disease of the breast, and angiosarcoma of the breast.

An analysis of patients with hormone receptor-positive, HER2-negative DCIS showed similar rates of 2-year invasive ipsilateral breast cancer recurrence among those who underwent active monitoring ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS ... tamoxifen reduced their overall risks for invasive recurrence, but not their risks for recurrence ...

One reporter is crediting actress Olivia Munn for saving her life. Inside Edition's Alison Hall shared an emotional post via ...

Women with Stage 0 breast cancer who got biannual mammograms and delayed surgery for two years fared as well as those who got immediate surgery.

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- Active monitoring for low-risk ductal ...